LATEST WEBINARS
Live date: Thursday 18 October. This webinar talks about the benefit of incorporating microsampling techniques in bioanalytical assays, as well as the effort required to overcome the challenges.
Available to view on demand. Accurate and precise biomarker measurement is critical to identifying diagnostic markers and druggable targets. Learn how quantitative mass spectrometry ensures proper biomarker measurement and characterization.
Live date: Thursday 27 September 2018. In this webinar, learn about utilizing xMAP® technology coupled with machine learning algorithms to detect polyps and early-stage colorectal cancer
Live date: Thursday 11 October 2018. Join our webinar to learn about the critical parameters related to the development of cell-based assays, the expected challenges and how binding assays could potentially be an acceptable replacement.
Available to view on demand. In this panel discussion, we hear from key experts in the field about their research and expertise, how they overcome key challenges associated with the technologies they work with and what they envision for the future of biomarker research and validation.
Available to view on demand. Selection and validation of biomarkers can be the difference between the success and failure of a pharmaceutical or biopharmaceutical drug development program.
Available to view on demand. Challenged to remove matrix interferences while dealing with the evolving complexity of biotherapeutics? This presentation illustrates how SelexION+ DMS can be efficiently utilized to overcome background interference challenges, which might otherwise limit assay capabilities.
Available to view on demand. In this panel discussion we gain a 360° perspective from leading CRO and pharmaceutical leaders on the sharing of scientific data.
Available to view on demand. We present a rare opportunity to see experts from across the pharmaceutical and CRO industries sharing perspectives on new technology integration in the field of bioanalysis.
Available to view on demand. Single molecule counting (SMC™) technology enables precise measurement of molecules at levels previously undetectable, down to the femtogram/mL levels, allowing researchers to identify new biomarkers or assist in therapeutic development with an improved view of efficacy, safety and time course studies. Find out more in this video webinar from Millipore Sigma (MA, USA).
Available to view on demand.
In this free panel discussion, our experts will provide insights into their own research with large molecules including the challenges they have had to overcome, key trends they have seen and their future outlook of the development of this field. There is also an opportunity for your own questions to be answered in the live Q&A.
Learn about new UHPLC column technologies and how to exploit them for improved characterization of biomacromolecules in our free upcoming webinar!
Latest News
Researchers from Scripps Research (CA, USA) have recently released a new technology platform designed to allow scientists to more easily quantify molecules from biological samples and make their results public.
The 39th BMSS annual meeting was held from 10–13 September 2018 in Cambridge, UK. In this conference report, Naamah Maundrell explores key highlights from the meeting including significant lectures from international experts.
A team from the UC Davis MIND Institute and NeuroPointDX (CA, USA) have developed a metabolic blood test that could identify approximately 17% of children with autism spectrum disorder (ASD).
Latest Features
As part of our Spotlight on the validation of biomarkers, we conducted a survey and compared the results to previous data. Find out more about the key trends, challenges and future potential for biomarker R&D in this informative infographic.
In this editorial Yu Shrike Zhang (Harvard Medical School; MA, USA), a previous finalist of the Bioanalysis Rising Star Award, discusses his research and hopes for the future. He details the emergence of organ-on-a-chip systems and how these platforms reproduce tissue functions outside the human body.
In this interview, Anita Tailor (Merck) discusses biomarker validation and standardization before predicting what the future may hold for biomarker research.
Drug Discovery and Development
Ligand-binding
Hybrid assays: the next big thing?
Evolution of fit-for-purpose biomarker validations: an LBA perspective
Mass Spectrometry
Cloud based platform designed to help scientists take measurements and share data publically
Sample preparation, extraction & collection
Hybrid assays: the next big thing?